PedAM
Pediatric Disease Annotations & Medicines
| Disease | multiple sclerosis |
| Phenotype | C0027765|neurological disease |
| Sentences | 5 |
| PubMedID- 23609782 | Drug development for multiple sclerosis (ms), as with any other neurological disease, faces numerous challenges, with many drugs failing at various stages of development. |
| PubMedID- 24363966 | Potential participants were excluded for significant neurological disease (e.g., history of stroke, multiple sclerosis), moderate or severe traumatic brain injury (with loss of consciousness), diagnosis of a current psychiatric illness, history of substance abuse with subsequent hospitalization, or any contraindications for magnetic resonance imaging (mri; e.g., some metal implants). |
| PubMedID- 26121034 | Nervonic acid is also applied to the treatment of neurological diseases associated with multiple sclerosis, adrenoleukodystrophy and zellweger syndrome [6–8]. |
| PubMedID- 21068308 | Mitochondrial dysfunction contributes to the pathogenesis of many neurological diseases, including multiple sclerosis (ms), but is not directly measurable in vivo. |
| PubMedID- 20890854 | We analyse the fsd in neurological diseases, as the outcome of medulla trauma, multiple sclerosis, epilepsy, alzheimer, parkinson, diabetes, outcome of pelvic surgery. |
Page: 1